[artículo] 
inThe American Journal of Psychiatry > Año 2023 - Vol. 180 - No. 3 (Marzo) . - pp. 190-199

Título :	Pharmacotherapies for treatment-resistant depression : how antipsychotics fit in the rapidly evolving therapeutic landscape
Tipo de documento:	texto impreso
Autores:	Manish K. Jha, Autor ; Sanjay J. Mathew, Autor
Fecha de publicación:	2023
Artículo en la página:	pp. 190-199
Idioma :	Inglés (eng) Idioma original : Inglés (eng)
Palabras clave:	Depresión resistente al tratamiento (TRD), Antipsicóticos atípicos, Ketamina, Esketamina, Psicodélicos, Antidepresivos, Trastornos depresivos
Resumen:	One in three adults with major depressive disorder (MDD) do not experience clinically significant improvement after multiple sequential courses of antidepressants and have treatment-resistant depression (TRD). The presence of TRD contributes to the morbidity and excess mortality associated with MDD and has been linked to significantly increased health care expenses. In the absence of a consensus definition of TRD, this report takes a broad approach by considering inadequate response to one or more courses of antidepressants and focuses on atypical antipsychotics that are approved by the U.S.
Link:	./index.php?lvl=notice_display&id=29971

[artículo] Pharmacotherapies for treatment-resistant depression : how antipsychotics fit in the rapidly evolving therapeutic landscape [texto impreso] / Manish K. Jha, Autor ; Sanjay J. Mathew, Autor . - 2023 . - pp. 190-199.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in The American Journal of Psychiatry > Año 2023 - Vol. 180 - No. 3 (Marzo) . - pp. 190-199

Palabras clave:	Depresión resistente al tratamiento (TRD), Antipsicóticos atípicos, Ketamina, Esketamina, Psicodélicos, Antidepresivos, Trastornos depresivos
Resumen:	One in three adults with major depressive disorder (MDD) do not experience clinically significant improvement after multiple sequential courses of antidepressants and have treatment-resistant depression (TRD). The presence of TRD contributes to the morbidity and excess mortality associated with MDD and has been linked to significantly increased health care expenses. In the absence of a consensus definition of TRD, this report takes a broad approach by considering inadequate response to one or more courses of antidepressants and focuses on atypical antipsychotics that are approved by the U.S.
Link:	./index.php?lvl=notice_display&id=29971